September 30, 2021

ActivSight ActivSurgical400x275Digital surgery firm Activ Surgical has announced it raised $45 million in a Series B financing round. The company’s hardware-agnostic platform and ActivInsights augmented reality (AR) software suite enables autonomous and collaborative surgery through integrating computer vision, artificial intelligence, machine learning, and robotics.

The company said it will use the Series B financing round to support the commercial availability of the ActivInsights software suite, including the first Insight – an AR-based overlay that displays tissue perfusion in real time without the use of traditional dyes. Activ Surgical also said it will use the funds to support commercialization in the U.S., pursue a CE mark in support of a global rollout, and further enhance the software platform and to develop its first ML-based insights.

The funding round was led by Cota Capital, a multi-stage investment firm focused on private and public modern enterprise technology companies. Seven new investors, including BAM Funds, Magnetar Capital, Mint Ventures, Castor Ventures, Dream One Vision and NVIDIA, join existing investors DNS Capital, Tao Capital Partners, LRVHealth, Rising Tide VC, GreatPoint Ventures (GPV) and ARTIS Ventures.

“Activ Surgical is on pace to solve the ‘last mile’ challenge for the surgical field and revolutionize the operating room as we know it,” said Bobby Yazdani, the founder and partner of Cota Capital. “The company’s cutting-edge product portfolio, coupled with its talented and experienced leadership team and staff, has the potential to deliver world-class surgery, regardless of geography or economic status, while helping to save lives and reduce medical complications. We are thrilled to be the lead investor on this Series B fundraise and are excited about what the future holds for the company and its technology.”

“2021 continues to be a critical year for Activ Surgical as we are laser-focused on democratizing surgical care at the global level,” said Todd Usen, CEO of Activ Surgical. “We received FDA clearance for our ActivSight enhanced visualization module that will power the ActivInsights software suite, and we were issued our first U.S. patent for ActivSight, as well as completed ouf first in-human clinical trials and have grown our team by 35%.”

For more information about the company and its products, visit the Activ Surgical website here.